Datapoint: CVS to Remove Humira From Most National Commercial Formularies

CVS Health Corp. announced on Jan. 3 that it would remove Humira (adalimumab) from CVS Caremark’s major national commercial template formularies and cover the drug’s biosimilars, effective April 1. The PBM said customers with Choice and Standard Opt Out commercial formularies would continue to have an option to have Humira on their formularies. CVS also noted that AbbVie, which manufactures Humira, will supply a co-branded adalimumab biosimilar to Cordavis, a wholly owned CVS biosimilar-focused subsidiary that launched this year. Nearly 90% of Caremark’s 25.3 million commercial pharmacy lives currently have preferred access to Humira, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 1/8/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 18

Datapoint: Arcutis Scores New Indication for Zoryve

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 17

Datapoint: Blue Shield of California Adds New Weight Loss, Diabetes Programs to Digital Health Platform

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 16

Datapoint: Sanford, Marshfield Clinic to Merge

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today